Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5718)
All Articles published online
|
Sep 21, 2014 (publication date) through Jan 5, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014; 20(35): 12581-12587 [PMID: 25253961 DOI: 10.3748/wjg.v20.i35.12581] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i35/12581.htm |
| Number | Citing Articles |
| 1 |
Ming-Han Hsieh, Tzu-Yu Kao, Ting-Hui Hsieh, Chun-Chi Kao, Cheng-Yuan Peng, Hsueh-Chou Lai, Po-Heng Chuang, Jung-Ta Kao, Ming-Lung Yu. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. PLOS ONE 2020; 15(12): e0244293 doi: 10.1371/journal.pone.0244293
|
| 2 |
Fatemeh Shafie, Fatemeh Nabavizadeh, Mehdi Shafie Ardestani, Mahshid Panahi, Soheila Adeli, Hedayat Samandari, Ghorbangol Ashabi. Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated rats. Canadian Journal of Physiology and Pharmacology 2019; 97(8): 691 doi: 10.1139/cjpp-2019-0141
|
| 3 |
Giulia Rovesti, Giulia Orsi, Andrikou Kalliopi, Caterina Vivaldi, Giorgia Marisi, Luca Faloppi, Francesco Giuseppe Foschi, Nicola Silvestris, Irene Pecora, Giuseppe Aprile, Eleonora Molinaro, Laura Riggi, Paola Ulivi, Matteo Canale, Alessandro Cucchetti, Emiliano Tamburini, Giorgio Ercolani, Lorenzo Fornaro, Pietro Andreone, Patrizia Zavattari, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini. Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors 2019; 6(3-4): 92 doi: 10.1159/000502714
|
| 4 |
Shaoming Song, Mingzhen Bai, Xiaofei Li, Shiyi Gong, Wenwen Yang, Caining Lei, Hongwei Tian, Moubo Si, Xiangyong Hao, Tiankang Guo. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2022; 22(3): 361 doi: 10.1080/14737159.2022.2049248
|
| 5 |
Wen‐Tsan Chang, Sheng‐Nan Lu, Kung‐Ming Rau, Ching‐Shan Huang, King‐Teh Lee. Increased cumulative doses and appearance of hand‐foot skin reaction prolonged progression free survival in sorafenib‐treated advanced hepatocellular carcinoma patients. The Kaohsiung Journal of Medical Sciences 2018; 34(7): 391 doi: 10.1016/j.kjms.2018.03.006
|
| 6 |
Brian C. Grieb, Laura W. Goff, Lipika Goyal, Crystal S. Denlinger. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. American Society of Clinical Oncology Educational Book 2019; (39): 248 doi: 10.1200/EDBK_237555
|
| 7 |
Yoshiyuki Wada, Yuko Takami, Tomoki Ryu, Hiroki Ureshino, Hajime Imamura, Shin Sasaki, Hideki Saitsu. A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression. Case Reports in Oncology 2020; 13(1): 379 doi: 10.1159/000506331
|
| 8 |
Maria-Katharina Ganten, Max Schuessler, Thomas Bruckner, Tom M. Ganten, Ronald Koschny. Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib. Oncology 2015; 89(2): 88 doi: 10.1159/000377681
|
| 9 |
Omar Abdel-Rahman, Angela Lamarca. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Review of Gastroenterology & Hepatology 2017; 11(1): 75 doi: 10.1080/17474124.2017.1264874
|
| 10 |
Lei Liu, Enxin Wang, Lin Li, Dongyu Chen, Kun Peng, Mengmeng Wang, Guohong Han. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. Canadian Journal of Gastroenterology and Hepatology 2019; 2019: 1 doi: 10.1155/2019/2576349
|
| 11 |
Hisami Imawari, Kazuki Fujimori, Jun‐ichiro Hiruma, Takafumi Numata, Noriyasu Sakai, Hidemitsu Tsutsui, Kazutoshi Harada. Perianal erosion in a patient with sorafenib‐induced hand‐foot syndrome: A case report. The Journal of Dermatology 2023; 50(10) doi: 10.1111/1346-8138.16853
|
| 12 |
Ming-Chin Yu, Tsung-Han Wu, Chao-Wei Lee, Yun-Shien Lee, Jang-Hau Lian, Chia-Lung Tsai, Sen-Yung Hsieh, Chi-Neu Tsai. Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma. Biomedical Journal 2021; 44(6): S73 doi: 10.1016/j.bj.2020.07.001
|
| 13 |
Christoph Zielinski, Istvan Lang, Semir Beslija, Zsuzsanna Kahan, Moshe J Inbar, Salomon M Stemmer, Rodica Anghel, Damir Vrbanec, Diethelm Messinger, Thomas Brodowicz. Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer 2016; 114(2): 163 doi: 10.1038/bjc.2015.419
|
| 14 |
Alessandro Granito, Sara Marinelli, Giulia Negrini, Saverio Menetti, Francesca Benevento, Luigi Bolondi. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therapeutic Advances in Gastroenterology 2016; 9(2): 240 doi: 10.1177/1756283X15618129
|
| 15 |
Valentina Bianchi, Erida Nure, Carmen Nesci, Marco Maria Pascale, Gabriele Sganga, Salvatore Agnes, Giuseppe Brisinda. Bridge Therapy before Liver Transplant for Advanced Hepatocellular Carcinoma. Medicina 2024; 60(6): 1010 doi: 10.3390/medicina60061010
|
| 16 |
R. Diaz-Beveridge, G. Bruixola, D. Lorente, J. Caballero, E. Rodrigo, Á. Segura, D. Akhoundova, A. Giménez, J. Aparicio. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clinical and Translational Oncology 2018; 20(3): 322 doi: 10.1007/s12094-017-1720-4
|
| 17 |
Suguru Hirose, Kazunori Ishige, Masamichi Yamaura, Tsuneo Mizui, Yoshiki Komatsu, Masaomi Nagase, Masashi Sato, Junji Hattori, Masato Endo, Naoyuki Hasegawa, Kuniaki Fukuda, Ichinosuke Hyodo. A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy. Clinical Journal of Gastroenterology 2020; 13(5): 902 doi: 10.1007/s12328-020-01154-z
|
| 18 |
Ping Wang, Gang Tan, Mingxin Zhu, Weidong Li, Bo Zhai, Xueying Sun. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Review of Gastroenterology & Hepatology 2018; 12(1): 1 doi: 10.1080/17474124.2017.1373018
|
| 19 |
Ming‐Lun Yeh, Chung‐Feng Huang, Ching‐I Huang, Ming‐Yen Hsieh, Nei‐Jen Hou, I‐Hung Lin, Po‐Cheng Liang, Yi‐Shan Tsai, Meng‐Hsuan Hsieh, Zu‐Yau Lin, Shinn‐Chern Chen, Chia‐Yen Dai, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. The Kaohsiung Journal of Medical Sciences 2019; 35(10): 624 doi: 10.1002/kjm2.12105
|
| 20 |
Tom M. Ganten, Rudolf E. Stauber, Eckardt Schott, Peter Malfertheiner, Robert Buder, Peter R. Galle, Thomas Göhler, Matthias Walther, Ronald Koschny, Guido Gerken. Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT Study. Clinical Cancer Research 2017; 23(19): 5720 doi: 10.1158/1078-0432.CCR-16-0919
|
| 21 |
Álvaro Díaz‐González, Marco Sanduzzi‐Zamparelli, Víctor Sapena, Ferran Torres, Neus LLarch, Gemma Iserte, Alejandro Forner, Leonardo da Fonseca, José Ríos, Jordi Bruix, María Reig. Systematic review with meta‐analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Alimentary Pharmacology & Therapeutics 2019; 49(5): 482 doi: 10.1111/apt.15088
|
| 22 |
Regiane S. S. M. Alencar, Luciana Kikuchi, Cláudia M. Tani, Aline L. Chagas, Cinira C. Camargo, Túlio E. F. Pfiffer, Paulo M. G. Hoff, Flair J. Carrilho. Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival. Journal of Cancer Therapy 2016; 7(04): 275 doi: 10.4236/jct.2016.74029
|
| 23 |
Fernanda Branco, Regiane S.M. Alencar, Fernanda Volt, Giovana Sartori, Andressa Dode, Luciana Kikuchi, Claudia M. Tani, Aline L. Chagas, Tulio Pfiffer, Paulo Hoff, Flair J. Carrilho, Angelo Alves de Mattos. The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib. Annals of Hepatology 2017; 16(2): 263 doi: 10.5604/16652681.1231587
|
| 24 |
Kazuo Kobayashi, Kazuyoshi Kawakami, Takashi Yokokawa, Takeshi Aoyama, Kenichi Suzuki, Takeru Wakatsuki, Mitsukuni Suenaga, Hitoshi Sato, Erika Sugiyama, Kensei Yamaguchi, Toshihiro Hama. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer. Oncology 2019; 96(4): 200 doi: 10.1159/000495989
|
| 25 |
Carol Mansfield, Sandy Srinivas, Connie Chen, A. Brett Hauber, Subramanian Hariharan, Ewa Matczak, Rickard Sandin. The effect of information on preferences for treatments of metastatic renal cell carcinoma. Current Medical Research and Opinion 2016; 32(11): 1827 doi: 10.1080/03007995.2016.1211521
|
| 26 |
Anne Hulin, Jeanick Stocco, Mohamed Bouattour. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clinical Pharmacokinetics 2019; 58(8): 983 doi: 10.1007/s40262-019-00740-w
|
| 27 |
Giovan Giuseppe Di Costanzo, Andrea Casadei Gardini, Giorgia Marisi, Francesco Giuseppe Foschi, Mario Scartozzi, Rocco Granata, Luca Faloppi, Stefano Cascinu, Nicola Silvestris, Oronzo Brunetti, Vincenzo Ostilio Palmieri, Giorgio Ercolani, Raffaella Tortora. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targeted Oncology 2017; 12(6): 795 doi: 10.1007/s11523-017-0522-5
|
| 28 |
Carina Hage, Sabine Hoves, Léanne Strauss, Stefan Bissinger, Ylva Prinz, Thomas Pöschinger, Fabian Kiessling, Carola H. Ries. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular Carcinoma. Hepatology 2019; 70(4): 1280 doi: 10.1002/hep.30666
|
| 29 |
Vicente Escudero-Vilaplana, Jose Luis Revuelta-Herrero, Roberto Collado-Borrell, Belen Marzal-Alfaro, Alvaro Gimenez-Manzorro, Ana Herranz-Alonso, María Sanjurjo-Saez. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice. Expert Opinion on Drug Safety 2019; 18(9): 861 doi: 10.1080/14740338.2019.1641197
|